Nektar Therapeutics (NASDAQ:NKTR) is among the hottest SMID-cap stocks so far in 2025. On November 10, Oppenheimer analyst Jay Olson reaffirmed his Outperform rating on Nektar Therapeutics ...
US spending figures may cause Fed to act, says exchange exec. Talk of BTC’s imminent sustainable recovery is premature, says ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback